Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Capital Leases (2016 - 2025)

Lineage Cell Therapeutics' Capital Leases history spans 12 years, with the latest figure at $32000.0 for Q4 2025.

  • For Q4 2025, Capital Leases fell 52.24% year-over-year to $32000.0; the TTM value through Dec 2025 reached $32000.0, down 52.24%, while the annual FY2025 figure was $32000.0, 52.24% down from the prior year.
  • Capital Leases reached $32000.0 in Q4 2025 per LCTX's latest filing, down from $40000.0 in the prior quarter.
  • In the past five years, Capital Leases ranged from a high of $133000.0 in Q1 2023 to a low of $12000.0 in Q3 2021.
  • Average Capital Leases over 5 years is $56400.0, with a median of $49500.0 recorded in 2025.
  • Peak YoY movement for Capital Leases: plummeted 74.19% in 2021, then surged 506.25% in 2023.
  • A 5-year view of Capital Leases shows it stood at $30000.0 in 2021, then soared by 180.0% to $84000.0 in 2022, then increased by 8.33% to $91000.0 in 2023, then fell by 26.37% to $67000.0 in 2024, then crashed by 52.24% to $32000.0 in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Capital Leases are $32000.0 (Q4 2025), $40000.0 (Q3 2025), and $48000.0 (Q2 2025).